Rocket Doctor AI's U.S. operation handled more patient visits per hour of clinician time in July and August than in the second quarter, according to an operational update the company issued from Vancouver on September 14.
The company reported 3,625 completed U.S. patient visits for the two months, equal to 93% of the 3,911 visits recorded across the whole second quarter. U.S. clinical hours reached 1,555 over the same period, equal to 78% of the second quarter's 1,987.5 hours.
The update followed the company's second-quarter financial and operational results, published on September 1, and was released ahead of a company town hall held that afternoon.
"Visit growth on its own can come from spending more," said Yazan Al Homsi, a Vancouver-based investor who holds shares in Rocket Doctor. "Visits per clinical hour is a lot harder to move, and it doesn't respond to marketing spend. If that ratio keeps improving as the platform grows, the model is becoming more efficient."
How the numbers compare
The company's comparison sets two months of the third quarter against three months of the second, so the percentages need adjusting before they can be read as growth rates. Converting both periods to monthly averages gives a like-for-like view. Rocket Doctor didn't present the figures this way; the calculations below are derived from its published totals.
On that basis, U.S. visits averaged about 1,813 a month in July and August, compared with about 1,304 a month in the second quarter, an increase of roughly 39%. Clinical hours averaged about 778 a month against roughly 663, an increase of about 17%.
Dividing visits by clinical hours gives the clearest single measure. The platform delivered about 2.33 completed visits per clinical hour in July and August, compared with about 1.97 in the second quarter, a rise of around 18%.
Why visits per clinical hour matter
In virtual care, clinician time is the scarce input. Software, scheduling and patient acquisition can be scaled relatively cheaply, but every consultation still requires a licensed professional. A platform that increases output per clinical hour can grow volume faster than its clinical costs, which is the basic condition for margins to widen as this kind of business grows.
Rocket Doctor describes itself as a physician-built, AI-powered healthcare technology company. Its platform gives doctors tools to run virtual or hybrid practices, alongside the Global Library of Medicine, a clinical decision support system the company says it developed with input from hundreds of physicians worldwide. The company says its technology has supported more than 350 doctors across over 750,000 patient visits.
The update doesn't break down the causes of the productivity change. Possible contributors include tighter scheduling, less administrative time per visit and a shift in the mix of visit types, and two months is too short a period to separate them with confidence.
The question has practical weight beyond Rocket Doctor. Physician supply is a constraint across much of North America, particularly outside large cities, and any model that lets a fixed pool of doctors see more patients without longer hours addresses a gap in access as well as a commercial one.
Rocket Doctor's shareholders include Yazan Al Homsi, whose investment thesis connecting AI-driven efficiency to gaps in healthcare access was profiled by IBTimes UK.
The revenue caveat
Higher visit numbers don't translate directly into reported revenue, and Rocket Doctor has been explicit on this point. The company currently recognizes certain U.S. revenues on a cash basis, which creates a timing lag between growth in patient visits and recognition of the associated revenue.
Reimbursement also depends on network status. For in-network patients, both the patient and the treating physician must be enrolled with the relevant insurer, Medicare or Medicaid for a claim to be eligible. During this early stage of its U.S. expansion, the company has chosen to give out-of-network patients access to the platform to drive adoption. Payer discretion may approve claims for those visits, and management is evaluating how to move out-of-network patients and physicians to in-network status.
Rising utilisation therefore points to demand and productivity, while revenue and margins will depend on payer mix and the pace of network conversion. You can't infer third-quarter revenue or profitability from these figures.
Yazan Al Homsi, who spent more than a decade in transaction advisory work at PwC and holds the CFA charter, said investors should keep those two measures separate. "The operating numbers are moving in the right direction," he said. "How quickly revenue follows depends on the payer work, and that's what I'll be watching over the next few quarters."
What to watch in the full quarter
Full third-quarter results will show whether September kept pace with July and August, and whether the improvement in visits per clinical hour held across a complete three-month period. Investors will also be looking for disclosure on the split between in-network and out-of-network visits, which bears directly on revenue.
Comparisons will become more reliable as the company reports consecutive full quarters on the same basis. A single two-month window can be influenced by seasonality and by the timing of clinician onboarding, so the trend over several periods will carry more weight than this one update.
For shareholders including Yazan Al Homsi, who publishes market commentary through Catalyst Wire, the ratio of visits to clinical hours is the figure to track. If it holds as volumes grow, Rocket Doctor's U.S. operations will have shown one of the harder things to demonstrate in telehealth: growth that doesn't depend on adding clinical time at the same rate.
